Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031
This is a first-in-human (FIH), multicenter, double-blind, placebo-controlled, parallel-group, escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031 administered by transforaminal epidural injection to subjects aged 18 to 75 years with neuropathic pain due to LSR.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1 | Experimental | Dose 1 (low dose: 1×1011 VG/500 μL solution) or Placebo |
|
| Cohort 2 | Experimental | Dose 2 (medium dose: 1×1012 VG/500 μL solution) or Placebo |
|
| Cohort 3 | Experimental | Dose 3 (high dose: 1×1013 VG/500 μL solution) or Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| KLS-2031 | Drug | KLS-2031 administered by transforaminal epidural injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| The safety and tolerability of KLS-2031 | Frequency and nature of AEs, laboratory test results, vital sign measurements, physical and complete neurological examinations, and 12-lead electrocardiograms (ECGs) | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52 |
| Measure | Description | Time Frame |
|---|---|---|
| Long-term safety and tolerability of KLS-2031 | Frequency and nature of AEs, laboratory test results, vital sign measurements, physical and complete neurological examinations, and 12-lead ECGs | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 78, Week 104 |
| Local safety and tolerability (including AEs, clinical laboratory parameters, and physical examination) of administration by transforaminal epidural injectionepidural injection as measured by the occurrence of injection site reactions |
Not provided
Inclusion Criteria:
To participate in the study, subjects must have met the following criteria at Visit 1 (Screening,
Day -56 to Day -15):
The subject signed a written informed consent for study participation including the 1-year double-blind treatment period and 1-year, open-label, long-term extension period.
Informed consent must have been obtained before any screening activities are conducted.
The subject, male or female, must have been between the ages of 18 and 75 years, inclusive.
The subject must have had a body mass index of ≤35 kg/m².
The subject must have had a diagnosis of pain due to LSR, with all of the following characteristics:
Pain in the leg (worse affected leg) was worse than pain in the back.
Exclusion Criteria:Subjects were excluded from the study if 1 or more of the following criteria were applicable:
The subject had:
Had lumbar stenosis with pain present solely upon walking. Presence of lumbar narrowing on MRI was acceptable if the pain was not solely present upon walking.
In the investigator's opinion, the subject was unable to reliably delineate or assess his/her own pain by anatomical location/distribution (eg, the subject could not reliably tell the difference between his/her back pain and lower limb pain and could not rate the intensity of each separately).
The subject had pain in the lower limbs solely upon walking and not at rest.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Todd Bertoch, MD | JBR Clinical Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kolon Investigative Site : CenExel JBR | Salt Lake City | Utah | 84107 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Other | Normal Saline (0.9%) administered by transforaminal epidural injection |
|
The occurrence of injection site reactions |
| Week 1, Week 2, Week 4, Week 12, Week 26, Week 52 |
| Change from baseline in weekly mean of the average daily pain score | calculated as the average of the subject's last 4 available PI-NRS daily scores in the week before the study visit | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104 |
| Change from baseline in Galer Neuropathic Pain Scale (Galer NPS) | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104 |
| Number and percentage of subjects who have ≥30% and ≥50% reduction from baseline in the average daily pain score (PI-NRS) | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104 |
| Time (number of weeks) to ≥30% and ≥ 50% reduction from baseline in the average daily pain score (PI-NRS) | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104 |
| Number and percentage of subjects who are much improved or very much improved from baseline | based on the Patient Global Impression of Change (PGIC) | Week 12, Week 26, Week 52, Week 104 |
| Change from baseline in the modified Modified Roland-Morris Disability Questionnaire (RMDQ) scores (back pain and leg pain) | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104 |
| Amount of rescue medication used (in terms of dosage/day) | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52 |
| Time to treatment failure | , defined as the day and time a subject starts pain medication other than acetaminophen for the treatment of neuropathic pain | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52 |
| Change from baseline in the Simple Profile of Moods States (POMS) - 2 Short Form total score and domain scores | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104 |
| Change from baseline in Daily Sleep Interference Scale (DSIS) score | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104 |
| Change from baseline in the Short Form-36 v2 (SF-36v2) score | Week 12, Week 26, Week 52, Week 104 |
| Assessment of suicidality | using the Columbia Suicide Severity Rating Scale (C-SSRS) | Week 1, Week 2, Week 4, Week 12, Week 26, Week 52 |